about
Complex adaptive immunity to enteric fevers in humans: lessons learned and the path forwardLive-Attenuated Bacterial Vectors: Tools for Vaccine and Therapeutic Agent DeliverySusceptibility to intestinal infection and diarrhoea in Zambian adults in relation to HIV status and CD4 count.New parameters available on Sysmex XE-5000 hematology analyzers contribute to differentiating dengue from leptospirosis and enteric fever.Cellular and cytokine responses to Salmonella enterica serotype Typhi proteins in patients with typhoid fever in BangladeshImproving Salmonella vector with rec mutation to stabilize the DNA cargoes.Characterization of anti-Salmonella enterica serotype Typhi antibody responses in bacteremic Bangladeshi patients by an immunoaffinity proteomics-based technologySalmonella enterica serovar Typhi live vector vaccines delivered intranasally elicit regional and systemic specific CD8+ major histocompatibility class I-restricted cytotoxic T lymphocytes.Oral immunization with ATP-dependent protease-deficient mutants protects mice against subsequent oral challenge with virulent Salmonella enterica serovar typhimurium.Early eradication of persistent Salmonella infection primes antibody-mediated protective immunity to recurrent infection.Impact of oral typhoid vaccination on the human gut microbiota and correlations with s. Typhi-specific immunological responses.Why the development of effective typhoid control measures requires the use of human challenge studies.Independent bottlenecks characterize colonization of systemic compartments and gut lymphoid tissue by salmonellaOral Wild-Type Salmonella Typhi Challenge Induces Activation of Circulating Monocytes and Dendritic Cells in Individuals Who Develop Typhoid Disease.Understanding paratyphoid infection: study protocol for the development of a human model of Salmonella enterica serovar Paratyphi A challenge in healthy adult volunteersOral Challenge with Wild-Type Salmonella Typhi Induces Distinct Changes in B Cell Subsets in Individuals Who Develop Typhoid Disease.Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a.Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid feverIntravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancerIn vitro Intestinal Mucosal Epithelial Responses to Wild-Type Salmonella Typhi and Attenuated Typhoid VaccinesSalmonella Typhi-specific multifunctional CD8+ T cells play a dominant role in protection from typhoid fever in humansCell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica Serovar Typhi strains used as live oral vaccines in humans.Interferon-driven alterations of the host's amino acid metabolism in the pathogenesis of typhoid fever.Vaccination without autoantigen protects against collagen II-induced arthritis via immune deviation and regulatory T cellsSerum bactericidal assay for the evaluation of typhoid vaccine using a semi-automated colony-counting method.Salmonella enterica serovar Typhi live vector vaccines finally come of ageKinetics of the natural, humoral immune response to Salmonella enterica serovar Typhi in Kathmandu, Nepal.Transcriptional response in the peripheral blood of patients infected with Salmonella enterica serovar Typhi.Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1.Importance of Salmonella Typhi-Responsive CD8+ T Cell Immunity in a Human Typhoid Fever Challenge Model.An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solution.Pathogenic bacteria as vaccine vectors: teaching old bugs new tricksHuman challenge studies: a review of adequacy of reporting methods and results.Vaccines based on structure-based design provide protection against infectious diseases.Deliberate Microbial Infection Research Reveals Limitations to Current Safety Protections of Healthy Human Subjects.Identification of Protective Antigens for Vaccination against Systemic Salmonellosis.Generation of specific effector and memory T cells with gut- and secondary lymphoid tissue- homing potential by oral attenuated CVD 909 typhoid vaccine in humans.Vaccines against cholera, typhoid fever and shigellosis for developing countries.Antibodies in action: role of human opsonins in killing Salmonella enterica serovar TyphiInsertion of a 59 amino acid peptide in Salmonella Typhimurium membrane results in loss of virulence in mice.
P2860
Q27694492-1E0FDA3D-E3E1-4C38-8BE8-D235B542EC27Q28084076-A3A33708-D640-4FE8-BE65-784E8A5D5DB9Q33401719-8FD37DEE-7EF3-461D-BA15-30579E13B8B7Q33425587-031AFA90-CAAF-4FF6-B970-55BD4BFC99FBQ33719547-E55C23A6-CEA2-46CE-9710-109A5330ABB9Q33814907-7BAE74E0-9F5B-44F8-B136-5A1B7A64085EQ34044935-182254C8-3140-4BF8-8CF5-A3894D40E570Q34127550-B8E31EAE-7CF9-43E0-B4C6-EBE38B2355A3Q34521851-19018157-C4AD-49BD-AF7D-5FEC7E722639Q34669382-EE10FFDE-6AF4-4C3E-8CDF-739A91772CB2Q34700862-824AB2B1-1D23-42E9-AA49-AC5DE90EFB01Q34709684-7A9342E2-1450-4D2B-A2B3-655F9E939D74Q35216497-A8E6AB9B-93C4-45E1-9B9B-1334AD5A286EQ35660952-77BD92CA-724B-4F6C-B21A-64DBBF943495Q35778973-9F3C44B6-1C3E-49C8-BE4C-0430418D802FQ36051755-B8466E1B-3FC0-46F6-B0C6-9C6136568355Q36105906-341D53A0-2C0D-4BC1-8A37-4D79C48E2FFEQ36313476-D841B04E-3F95-48F1-8A96-E2D5E90BF539Q36593956-E795C824-E2D9-4AC7-9464-FED7B13767EFQ36601934-DC036E70-1129-4318-87DB-9EE4882990F8Q36634226-48A12B3D-F1ED-41F8-97B6-65BCCDD218FFQ36854773-02B5E557-0D5C-4D01-852A-7B5D23EE7CCBQ36949893-233F24A8-0791-4981-9343-708E5B2D5872Q37008483-07BFCFB2-2DB0-4F28-B4E6-34D2E2109EF8Q37094977-2C3E45C6-AF8A-455D-8BF4-8A577B595182Q37106127-710B4224-8DB5-403F-A25C-AE16D8F8651EQ37374692-3C842897-F9C6-421F-A0A7-23A4023BEDBBQ37471843-E2F0BFC5-2543-4442-A6C1-69AEBB73C79DQ37596462-12482752-6994-465B-ADD5-B49A20DFE0BBQ37675513-B8DA6D22-8772-4F35-9A06-B50F8C5F1534Q37696581-243D5D1C-C5DE-4C98-82AD-A7D26CD5B2E7Q37821773-E210C0F3-3386-490D-8D4F-795E908BAB78Q37996090-5A51B821-4029-4C90-8393-68A00F13AFFCQ38148782-44A5CF3D-B189-41A3-9C4A-0200FA7B9893Q38242596-C95165A2-879C-4BF3-B9D6-476E04D68C8EQ38243324-C89AC711-5D0C-44B9-B594-EDA76838D7D3Q39081934-7C7C9013-49CD-4F0A-8785-3C95D832DF73Q39217803-0687D033-269E-488B-904C-2DD838A3C497Q39744171-9B96DEAD-0E1B-4205-B091-DC57E5427E4BQ41744757-5B221CC8-3A8F-44CB-B188-51AC759034B2
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Host-Salmonella interaction: human trials.
@ast
Host-Salmonella interaction: human trials.
@en
Host-Salmonella interaction: human trials.
@nl
type
label
Host-Salmonella interaction: human trials.
@ast
Host-Salmonella interaction: human trials.
@en
Host-Salmonella interaction: human trials.
@nl
prefLabel
Host-Salmonella interaction: human trials.
@ast
Host-Salmonella interaction: human trials.
@en
Host-Salmonella interaction: human trials.
@nl
P2093
P1476
Host-Salmonella interaction: human trials.
@en
P2093
C O Tacket
M B Sztein
M M Levine
P304
P356
10.1016/S1286-4579(01)01487-3
P577
2001-11-01T00:00:00Z